Shopping Cart
- Remove All
Your shopping cart is currently empty
SD-169 (SD 169) is a selective and ATP competitive the MAP kinases p38α and p38β inhibitor.

| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 50 mg | $34 | In Stock | |
| 100 mg | $51 | In Stock | |
| 200 mg | $75 | In Stock | |
| 1 mL x 10 mM (in DMSO) | $29 | In Stock |
| Description | SD-169 (SD 169) is a selective and ATP competitive the MAP kinases p38α and p38β inhibitor. |
| Targets&IC50 | p38α MAPK:3.2 nM (IC50), p38β MAPK:122 nM (IC50) |
| In vivo | Animals were gavaged with Scios SD-169 (10 or 30 mg/kg) or excipient (PEG300) 1 day before and daily after crush injury to the sciatic nerve.?SD-169 is a proprietary oral inhibitor of p38 MAPK activity.?The rate of axonal regeneration was determined by the functional pinch test and was significantly increased in treated animals 8 days after crush injury (P < 0.05;?30 mg/kg dose).?In SD-169-treated animals with nerve transection, nerve fibers regenerating through a silicone chamber were morphologically more mature than untreated nerves when observed 28 days after transection.?TNF immunofluorescence of distal nerve segments after crush injury suggested that SD-169 reduced SC TNF protein[1]. |
| Synonyms | SD 169 |
| Molecular Weight | 160.17 |
| Formula | C9H8N2O |
| Cas No. | 1670-87-7 |
| Smiles | NC(=O)c1ccc2[nH]ccc2c1 |
| Relative Density. | 1.328g/cm3 |
| Color | White |
| Appearance | Solid |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | ||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 10 mg/mL (62.43 mM), Sonication is recommended. | ||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 1 mg/mL (6.24 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | ||||||||||||||||||||||||||||||
Solution Preparation Table | |||||||||||||||||||||||||||||||
DMSO
| |||||||||||||||||||||||||||||||

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.